Dr. Tarek Ezzeddine, MD
Internal Medicine (Internal Medicine Physician)
8250 White Oak Ave Ste 106
Rancho Cucamonga, CA 91730
Who else practices at this address →
San Bernardino County includes primary care (5% of residents) and mental health (26% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 27
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 82
Licensed in California since 2014, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
CA license C133690 (first issued 2014; current) -
Pediatrics Physician
CA license C133690 (first issued 2014; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- San Antonio Regional Hospital Upland, CA
Medical groups
- Mountain View Urgent Care Group Inc (32 clinicians)
- Onyx Medical Group Inc (11 clinicians)
- Remedial PAtients Care Inc (8 clinicians)
- Careone Healthcare Group Inc (3 clinicians)
- Specialized Urgent Care (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 82
- Services billed
- 584
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 59 | 34 |
| Residence visit for new patient with moderate level of medical decision making, per day, if using time, at least 60 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 9 companies. The companies reported $931,175 in research payments for these studies, mostly to the institutions running them.
- Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity
Hoffmann-la Roche Limited - BXCL501401
Bioxcel Therapeutics, Inc. - A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Rel…
AstraZeneca Pharmaceuticals LP - A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia VENTURA-5
Janssen Research & Development, LLC - A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06585787 - A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderl…
Janssen Research & Development, LLC - Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with T2DM
Genentech, Inc. - Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT05980949 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
AbbVie Inc. · Active, not recruiting · NCT06063967 - Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
Genzyme Corporation · Active, not recruiting · NCT05097287
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.